Profile data is unavailable for this security.
About the company
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
- Revenue in HKD (TTM)2.28bn
- Net income in HKD-2.65bn
- Incorporated2013
- Employees2.18k
- LocationZai Lab Ltd4560 Jinke Road, Bldg. 1, 4/F, PudongSHANGHAI 201210ChinaCHN
- Phone+86 2 161632588
- Fax+86 2 161632570
- Websitehttps://www.zailaboratory.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InnoCare Pharma Ltd | 797.43m | -681.60m | 9.00bn | 1.09k | -- | 1.04 | -- | 11.29 | -0.4041 | -0.4041 | 0.4726 | 4.38 | 0.073 | 1.39 | 3.39 | 732,259.20 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| Keymed Biosciences Inc | 382.33m | -388.01m | 9.48bn | 897.00 | -- | 2.94 | -- | 24.80 | -1.49 | -1.49 | 1.45 | 11.53 | 0.0906 | 0.7314 | 26.14 | 426,233.70 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Shanghai Henlius Biotech Inc | 5.83bn | 589.56m | 10.24bn | 3.64k | 17.42 | 4.33 | 10.48 | 1.76 | 1.08 | 1.08 | 10.67 | 4.36 | 0.5731 | 1.95 | 9.10 | 1,601,627.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| Luye Pharma Group Ltd | 6.63bn | 575.08m | 10.68bn | 5.27k | 18.49 | 0.7896 | 7.97 | 1.61 | 0.1536 | 0.1536 | 1.78 | 3.60 | 0.247 | 2.42 | 3.60 | 1,258,624.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.41bn | 1.21bn | 11.62bn | 1.05k | 9.93 | 3.17 | 8.49 | 3.41 | 1.86 | 1.86 | 5.24 | 5.84 | 0.7585 | 3.56 | 3.83 | 3,245,003.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
| SSY Group Ltd | 6.46bn | 1.32bn | 14.10bn | 5.60k | 10.73 | 2.03 | 8.07 | 2.18 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Zai Lab Ltd | 2.28bn | -2.65bn | 15.22bn | 2.18k | -- | 2.51 | -- | 6.69 | -2.74 | -2.74 | 2.35 | 6.12 | 0.2697 | 2.84 | 5.61 | -- | -31.41 | -37.72 | -36.81 | -42.72 | 62.86 | 64.75 | -116.45 | -282.44 | 4.43 | -- | 0.0596 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| 3SBio Inc | 8.44bn | 1.67bn | 15.56bn | 5.41k | 9.46 | 1.01 | 7.50 | 1.84 | 0.6742 | 0.6742 | 3.46 | 6.32 | 0.3426 | 1.58 | 7.01 | 1,559,639.00 | 6.95 | 7.44 | 9.03 | 9.29 | 84.98 | 82.91 | 20.30 | 21.50 | 2.26 | 22.72 | 0.2266 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Simcere Pharmaceutical Group Ltd | 7.13bn | 771.76m | 16.21bn | 7.03k | 21.45 | 2.08 | 14.66 | 2.27 | 0.2895 | 0.2895 | 2.74 | 2.98 | 0.6106 | 3.53 | 2.65 | 1,015,331.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 14.84bn | 2.92bn | 16.59bn | 15.00k | 5.69 | 1.21 | 4.70 | 1.12 | 1.61 | 1.61 | 8.16 | 7.57 | 0.6871 | 3.36 | 6.15 | 989,036.00 | 13.51 | 7.89 | 20.52 | 12.64 | 46.11 | 44.17 | 19.66 | 12.73 | 1.74 | -- | 0.1055 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 14.67 |
| Grand Pharmaceutical Group Ltd | 10.53bn | 1.88bn | 18.32bn | 10.53k | 9.63 | 1.19 | 8.01 | 1.74 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Genscript Biotech Corp | 6.56bn | -746.58m | 19.34bn | 6.94k | -- | 1.77 | -- | 2.95 | -0.3544 | -0.3544 | 3.11 | 5.13 | 0.283 | 7.59 | 5.45 | 946,330.80 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| WuXi XDC Cayman Inc | 2.29bn | 306.15m | 19.40bn | 1.18k | 57.90 | 3.29 | 52.44 | 8.46 | 0.2798 | 0.2798 | 2.13 | 4.92 | -- | -- | -- | 1,946,690.00 | -- | -- | -- | -- | 26.35 | -- | 13.35 | -- | 4.03 | -- | 0.0005 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Zai Lab Ltd's reporting currency: Hong Kong Dollar HKD
17.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 37.79m | 3.81% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 23.29m | 2.35% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 19.33m | 1.95% |
| Wellington Management Hong Kong Ltd.as of 23 May 2024 | 17.58m | 1.77% |
| Baillie Gifford & Co.as of 30 Apr 2024 | 15.69m | 1.58% |
| BlackRock Fund Advisorsas of 09 May 2024 | 15.53m | 1.57% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 12.00m | 1.21% |
| UBS Asset Management Switzerland AGas of 09 May 2024 | 10.20m | 1.03% |
| Wellington Management International Ltd.as of 23 May 2024 | 9.74m | 0.98% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 7.63m | 0.77% |
More ▼
Data from 31 Dec 2023 - 30 May 2024Source: FactSet Research Systems Inc.
